Healthcare ❯ Pharmaceuticals

Clinical Trials

Drug Development Weight Loss Drugs Efficacy Studies Cancer Treatment Sanofi Phase 2 Trials HIV Prevention Mental Health Ketamine Weight-Loss Drugs Drug Safety Oncology Treatments Patient Safety PrEP Mpox Treatment Puberty Blockers Depression Treatments Multiple Myeloma Diabetes Treatment Neurological Conditions Drug Approval Drug Supply New Chemical Entities ALS Regulatory Approval Weight Loss Treatments Drug Efficacy Weight Management Psychedelic Research Chronic Conditions HARMONi Trials Pulmonary Arterial Hypertension Epilepsy Treatments Metabolic Diseases Rare Diseases Atopic Dermatitis Pulmonary Sarcoidosis Phase 2 Obesity Treatments Vaccine Development Regulatory Approvals Response Rate Drug Effectiveness Phase 3 Trials Semaglutide Candidates GLP-1s Competition Phase 3

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

The program narrows to non‑relapsing secondary progressive MS, with the U.S. decision now expected by the end of the first quarter of 2026.

Kymera Jumps on KT-621 Phase 1b Win, Advancing Oral STAT6 Degrader Into Phase 2b

Praxis Relutrigine Study Halted Early for Efficacy as FDA Review Meeting Set

Viking Therapeutics Jumps After Wider Q3 Loss as R&D Ramp Signals Obesity-Drug Progress

Quoin Pharmaceuticals Shares Jump on $104.5 Million Private Placement With $16.8 Million Upfront

Single 100-Microgram Dose of LSD Drug Eased GAD for 12 Weeks in JAMA Trial